OP1 A novel biomarker of cardiovascular ageing in the general population using machine learning
作者
Mit Shah,Marco Henrique de Almeida Inácio,Chang Lu,Pierre-Raphaël Schiratti,Sean Lee Zheng,Vladimir Losev,Wenjai Bai,Christian Bender,Daniel F. Freitag,Declan P. O’Regan
Introduction Population ageing places an increasing burden on healthcare resources, driven primarily through cardiovascular morbidity. Ageing in the cardiovascular system can be detected through structural and functional decline using cardiac magnetic resonance (CMR). We aimed to use CMR data and a machine learning approach to develop a biomarker of cardiovascular ageing to quantify and discover modulators of this process. Methods We studied 39,559 participants in the UK Biobank study with a CMR scan. A Catboost model was trained to learn healthy cardiovascular ageing in 5065 healthy individuals from CMR data, including measures of cardiovascular structure, function and T1 mapping. This model subsequently predicted cardiovascular age in 34,147 new individuals. Regression was used to quantify effect-sizes of diseases and lifestyle factors. Genome-wide association study (GWAS, n = 29,506) was performed to identify potential genetic contributors to the process and additionally develop a polygenic risk score to identify phenotypic associations using a phenome-wide approach (n = 415,622). Results Hypertension was associated with +1.58 years premature cardiovascular ageing, as was diabetes (+0.74 years), smoking (+0.03 years/pack year) and alcohol (+0.02 years/gram per day). Elevated heart rate, visceral fat and alkaline phosphatase were also associated with premature ageing. Telomere length and lung function were associated with favourable ageing. GWAS revealed titin, elastin, pro-inflammatory proteins (PLCE1, TREM2) and calcium regulators (MICU3) were significant associations of cardiovascular ageing. Conclusion This is the first biomarker for cardiovascular ageing derived from conventional CMR parameters. Potential applications include personalised risk profile and cardioprotective interventions, and discovering novel drug targets to attenuate cardiovascular ageing.